Literature DB >> 22647732

Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

Suchitra Prasad1, Adam P Kohm, Jeffrey S McMahon, Xunrong Luo, Stephen D Miller.   

Abstract

Type 1 diabetes (T1D) is mediated by destruction of pancreatic β-cells by CD4 and CD8 T cells specific for epitopes on numerous diabetogenic autoantigens resulting in loss of glucose homeostasis. Employing antigen-specific tolerance induced by i.v. administration of syngeneic splenocytes ECDI cross-linked to various diabetogenic antigens/epitopes (Ag-SP), we show that epitope spreading plays a functional role in the pathogenesis of T1D in NOD mice. Specifically, Ag-SP coupled with intact insulin, Ins B(9-23) or Ins B(15-23), but not GAD65(509-528), GAD65(524-543) or IGRP(206-214), protected 4-6 week old NOD mice from the eventual development of clinical disease; infiltration of immune cells to the pancreatic islets; and blocked the induction of DTH responses in a Treg-dependent, antigen-specific manner. However, tolerance induction in 19-21 week old NOD mice was effectively accomplished only by Ins-SP, suggesting Ins B(9-23) is a dominant initiating epitope, but autoimmune responses to insulin epitope(s) distinct from Ins B(9-23) emerge during disease progression.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22647732      PMCID: PMC3434243          DOI: 10.1016/j.jaut.2012.04.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  44 in total

Review 1.  Epitope spreading in immune-mediated diseases: implications for immunotherapy.

Authors:  Carol L Vanderlugt; Stephen D Miller
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

2.  Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood.

Authors:  Jacqueline D Trudeau; Carolyn Kelly-Smith; C Bruce Verchere; John F Elliott; Jan P Dutz; Diane T Finegood; Pere Santamaria; Rusung Tan
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 3.  Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Authors:  Jeffrey A Bluestone; Kevan Herold; George Eisenbarth
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

4.  Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.

Authors:  C L Vanderlugt; K L Neville; K M Nikcevich; T N Eagar; J A Bluestone; S D Miller
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

5.  Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice.

Authors:  Enayat Nikoopour; Christian Sandrock; Katrina Huszarik; Olga Krougly; Edwin Lee-Chan; Emma L Masteller; Jeffrey A Bluestone; Bhagirath Singh
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

6.  Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy.

Authors:  Charles B Smarr; Chia-Lin Hsu; Adam J Byrne; Stephen D Miller; Paul J Bryce
Journal:  J Immunol       Date:  2011-10-05       Impact factor: 5.422

7.  Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus.

Authors:  S M Trigwell; P M Radford; S R Page; A C Loweth; R F James; N G Morgan; I Todd
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

8.  T cell response to preproinsulin I and II in the nonobese diabetic mouse.

Authors:  Philippe Halbout; Jean-Paul Briand; Chantal Bécourt; Sylviane Muller; Christian Boitard
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

9.  Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes.

Authors:  Scott M Lieberman; Anne M Evans; Bingye Han; Toshiyuki Takaki; Yuliya Vinnitskaya; Jennifer A Caldwell; David V Serreze; Jeffrey Shabanowitz; Donald F Hunt; Stanley G Nathenson; Pere Santamaria; Teresa P DiLorenzo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

10.  Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase.

Authors:  Elmar Jaeckel; Ludger Klein; Natalia Martin-Orozco; Harald von Boehmer
Journal:  J Exp Med       Date:  2003-06-09       Impact factor: 14.307

View more
  53 in total

Review 1.  Auto-antigen and Immunomodulatory Agent-Based Approaches for Antigen-Specific Tolerance in NOD Mice.

Authors:  Ethan J Bassin; Jon D Piganelli; Steven R Little
Journal:  Curr Diab Rep       Date:  2021-02-06       Impact factor: 4.810

Review 2.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  Engineering Biomaterials to Direct Innate Immunity.

Authors:  R S Oakes; E Froimchuk; C M Jewell
Journal:  Adv Ther (Weinh)       Date:  2019-02-27

4.  Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C.

Authors:  K Sumida; S Shimoda; S Iwasaka; S Hisamoto; H Kawanaka; T Akahoshi; T Ikegami; K Shirabe; N Shimono; Y Maehara; C Selmi; M E Gershwin; K Akashi
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

Review 5.  Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.

Authors:  Suchitra Prasad; Dan Xu; Stephen D Miller
Journal:  Rev Diabet Stud       Date:  2012-12-28

6.  The Use of Biodegradable Nanoparticles for Tolerogenic Therapy of Allergic Inflammation.

Authors:  Charles B Smarr; Stephen D Miller
Journal:  Methods Mol Biol       Date:  2018

7.  Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.

Authors:  Meghan L Marre; John W McGinty; I-Ting Chow; Megan E DeNicola; Noah W Beck; Sally C Kent; Alvin C Powers; Rita Bottino; David M Harlan; Carla J Greenbaum; William W Kwok; Jon D Piganelli; Eddie A James
Journal:  Diabetes       Date:  2018-04-13       Impact factor: 9.461

8.  Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes.

Authors:  Li Zhang; Frances Crawford; Liping Yu; Aaron Michels; Maki Nakayama; Howard W Davidson; John W Kappler; George S Eisenbarth
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 9.  Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles.

Authors:  Ryan M Pearson; Joseph R Podojil; Lonnie D Shea; Nicholas J C King; Stephen D Miller; Daniel R Getts
Journal:  Nanomedicine       Date:  2018-10-21       Impact factor: 5.307

10.  Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes.

Authors:  Angela Lombardi; Erlinda Concepcion; Hanxi Hou; Hanane Arib; Mihaly Mezei; Roman Osman; Yaron Tomer
Journal:  J Autoimmun       Date:  2020-09-17       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.